Long-acting injectable (LAI) antipsychotics are superior to oral antipsychotics for preventing rehospitalization in older adults with schizophrenia, researchers report in a study published online in The American Journal of Geriatric Psychiatry.
The analysis reviewed 1-year rehospitalization rates of 1168 adults over 60 years of age with schizophrenia who underwent psychiatric hospitalization between 2006 and 2017. According to Psychiatric News Alert, at discharge 151 participants had prescriptions for LAI antipsychotics and 1017 participants had prescriptions for oral antipsychotics.
Patients treated with LAI antipsychotics had a significantly lower rehospitalization rate at 1 year after discharge (53.6%), compared with patients treated with oral antipsychotics (66.1%). Furthermore, patients in the LAI group had a significantly longer time to rehospitalization than patients in the oral group (median 257 days vs 115 days).
In addition to LAIs, other factors associated with a longer time to rehospitalization were shorter index hospitalizations and fewer previous hospitalizations.
Researchers also reported significant growth of second-generation LAI prescriptions during the study period, which they attributed to the better side-effect profile of second-generation LAIs compared with first-generation LAIs.
“More studies investigating the effectiveness of long-acting injectable antipsychotics in elderly patients with schizophrenia are needed in the future,” researchers advised.
Lin C, Chen F, Chan H, Hsu C. A comparison of long-acting injectable antipsychotics with oral antipsychotics on time to rehospitalization within one year of discharge in elderly patients with schizophrenia. The American Journal of Geriatric Psychiatry. 2019 August 9;[Epub ahead of print].